Work

Anxiety, Depression, and Impaired Quality of Life in Primary Aldosteronism: Why We Shouldn’t Ignore It!

Year: 2017
Type: article
Abstract: Many endocrinopathies are associated with impaired quality of life and psychiatric comorbidities. Personality changes are characteristic features of endocrine diseases and can even be the dominating symptom. In such circumstances, a patient will be treated for an apparent primary psychiatric condition, whereas the underlying endocrine diagnosis is delayed for month or even years. It is textbook knowledge that mania and psychosis may be found in patients with severe hyperthyroidism, whereas patients with Cushing syndrome frequently have depressive symptoms and cognitive disturbances. In pituitary diseases, the spectrum depends on the underlying hyperfunction or hypofunction: acromegalic patients often have maladaptive personality traits and higher rates of affective disorders, and patients with prolactinoma have changes in sleep pattern and cognition. Primary aldosteronism affects, depending on hypertension prevalence in the respective target populations, 1% to 2% of the general population (1). It comes with an increased risk of cardiovascular and renal comorbidities compared with hypertensive patients of similar age, sex, and blood pressure. Contrary to other endocrinopathies, psychiatric comorbidities in patients with primary aldosteronism have only recently become a focus of attention. Several early case reports identified depression and anxiety disorders as symptoms associated with primary aldosteronism (2–5). It was not until 2006 that Sonino et al. (6) investigated 10 consecutive patients with primary aldosteronism using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders and the Diagnostic Criteria for Psychosomatic Research interview. As it turned out, seven patients qualified for the diagnosis of a generalized anxiety disorder, and one patient had an obsessive-compulsive disorder (Table 1 and Table 2) (6–11). The patients also reported demoralization (n = 5), persistent somatization (n = 2), and irritable mood (n = 1). In a controlled study, the same authors confirmed this finding in an independent cohort of 23 patients with primary aldosteronism in comparison with matched essential hypertensive patients and normotensive controls (7). Again, there was a striking prevalence of anxiety and, to a lesser degree, depression in the patients. Prevalence of Depression and Anxiety in Patients With Primary Aldosteronism Abbreviations: DCPR, Diagnostic Criteria for Psychosomatic Research; EH, essential hypertension; GAD-7, seven-item General Anxiety Disorder scale; MRA, mineralocorticoid receptor antagonist; NA, not available; PA, primary aldosteronism; PHQD, Brief Patient Health Questionnaire; PSI, Psychosocial Index; SCID, Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders IV. Prevalence of Depression and Anxiety in Patients With Primary Aldosteronism Abbreviations: DCPR, Diagnostic Criteria for Psychosomatic Research; EH, essential hypertension; GAD-7, seven-item General Anxiety Disorder scale; MRA, mineralocorticoid receptor antagonist; NA, not available; PA, primary aldosteronism; PHQD, Brief Patient Health Questionnaire; PSI, Psychosocial Index; SCID, Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders IV. Prevalence of Impaired Quality of Life in Patients With Primary Aldosteronism Abbreviations: MRA, mineralocorticoid receptor antagonist; PA, primary aldosteronism; QoL, quality of life; SF-36, Medical Outcomes Study Short Form 36 General Health Survey. Prevalence of Impaired Quality of Life in Patients With Primary Aldosteronism Abbreviations: MRA, mineralocorticoid receptor antagonist; PA, primary aldosteronism; QoL, quality of life; SF-36, Medical Outcomes Study Short Form 36 General Health Survey. In a large cross-sectional study, we studied 132 patients with primary aldosteronism in different phases of the disease: at diagnosis before initiation of specific treatment, 4 years after adrenalectomy, or 5 years after initiation of mineralocorticoid antagonist treatment (8). We assessed anxiety and depression by the following validated questionnaires: seven-item General Anxiety Disorder scale and Brief Patient Health Questionnaire. Compared with the normal German population, patients with primary aldosteronism had higher prevalence rates of depression and anxiety, with females being more severely affected than males. The first study to investigate the longitudinal impact of adrenalectomy and mineralocorticoid antagonist treatment on quality of life was the Stowasser group from Australia. In their pilot study, quality of life was evaluated prospectively using the Medical Outcomes Study Short Form 36 General Health Survey questionnaire before and 3 and 6 months after unilateral adrenalectomy in 22 patients with primary aldosteronism (9). Preoperatively, the patients had impaired quality of life in each quality-of-life domain compared with the Australian general population. Substantial improvements were seen as early as 3 months after surgery and, to a similar degree, 6 months after adrenalectomy. In a parallel protocol involving 21 patients with bilateral adrenal hyperplasia treated with spironolactone or amiloride, quality of life at 3 months was again lower compared with adrenalectomized patients but normalized at 6 months (10). In summary, these studies suggested that the outcome of surgically and medically treated patients might be similar in terms of quality of life. However, limitations of both studies have been the relative short follow-up and the limited number of patients studied. Hence, whether long-term quality-of-life outcome of medical treatment is equivalent to adrenalectomy remained an open question. Because cardiovascular and renal outcomes seem to be similar between surgical and medical treatment (12), quality of life might become the only justification for surgery. In the study by Velema et al. (11) published in this issue of Journal of Clinical Endocrinology & Metabolism, the authors investigated quality of life in patients of the Subtyping Primary Aldosteronism: A Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan (SPARTACUS) trial. This was a randomized trial performed in 200 patients with primary aldosteronism in 12 Dutch centers and 1 Polish center. The primary objective of this trial was to compare the blood pressure outcome of computed tomography–based subtyping with that of adrenal vein sampling–based subtyping. Surprisingly, blood pressure outcome (quantified as daily defined doses) was similar in both groups with a nonsignificant difference of remission rates. Ninety-two patients were subjected to unilateral adrenalectomy and 92 patients to treatment with mineralocorticoid antagonist, and the authors used this cohort to analyze quality of life prospectively 6 and 12 months after start of therapy. Quality of life prior to initiation of treatment was low in both groups, in line with the Stowasser group data, indicating a significant disease burden. Of note, female patients had worse scores than males. Quality of life improved substantially in both treatment arms although to a lesser degree in the mineralocorticoid receptor antagonist group. At last follow-up after 12 months, quality of life of the surgery group was equivalent to or better than that of the normal population. In contrast, patients with bilateral adrenal hyperplasia treated with mineralocorticoid antagonists had improvements in quality of life without full recovery. More important, the surgery group had clinically meaningful higher scores than the mineralocorticoid antagonist group. In summary, based on quality of life, this large prospective study is in favor of adrenalectomy. This could be a strong argument for screening and subtyping of primary aldosteronism: find the patient with unilateral aldosteronism because long-term quality of life is better than putting the patient on mineralocorticoid antagonist therapy. That screening and subtyping of primary aldosteronism in general is a cost-effective has been recently shown (13). Currently, it remains an open question whether depression, anxiety, and consecutively impaired quality of life are direct consequences of aldosterone excess via endocrine effects on the brain or result from uncontrolled hypertension. Evidence can be found for both concepts. The mineralocorticoid receptor function in the central nervous system has been implicated in the response to antidepressive treatment and in the mediation of anxiety-related behavior. Moreover, the mineralocorticoid receptor seems also to be involved in emotional memory processes [as reviewed by Künzel (14)]. A recent paradigm shift has been the implication of direct aldosterone actions at the level of mineralocorticoid receptors in the central nervous system. Formerly thought to be occupied by glucocorticoids in most parts of the brain, there is accumulating evidence that aldosterone acts selectively in relevant mood-regulating brain areas, without competing with cortisol/corticosterone [reviewed by Murck et al. (15)]. In a rat model of depression, subcutaneous aldosterone given via somotic minipumps induced an anhedonic state manifested by decreased sucrose preference and a depression-like behavior in the forced swim test (16). On the other hand, besides direct aldosterone actions on the brain, uncontrolled or treatment-resistant hypertension by itself could be a major factor causing anxiety and impaired quality of life (17). Patients with primary aldosteronism report frequent visits to outpatient clinics for drug adjustments and unsuccessful attempts to reach blood pressure targets. They may have hypertensive emergencies and insecurities resulting from high blood pressure readings when performing home blood pressure measurements. Resistant hypertension also could lead to cerebrovascular impairment and white matter lesions, in line with the “vascular hypothesis” of depression (14). An alternative explanation comes from the steroid secretion patterns in primary aldosteronism. Using a mass spectrometry–based analysis of the 24-hour urine steroid metabolome in 174 patients with newly diagnosed primary aldosteronism, we have recently reported significant cortisol cosecretion in most patients (18). Quantitatively, the glucocorticoid excess was more pronounced than that found in so-called subclinical Cushing syndrome (now termed autonomous cortisol secretion) but less than that typical for full-blown adrenal Cushing syndrome. Unilateral adrenalectomy abolished aldosterone excess and normalized glucocorticoid cosecretion. Based on the simultaneous presence of Cushing and Conn syndromes, we termed this endocrine constellation Connshing syndrome. It is an attractive concept, that cortisol cosecretion might be detrimental for psychological well-being in untreated primary aldosteronism, and it could explain differences in quality of life in response to surgery or medical treatment. Although adrenalectomy removes both mineralocorticoid and glucocorticoid excess, patients treated with mineralocorticoid receptor antagonist might have persistent and unopposed glucocorticoid excess negatively affecting quality of life. Financial Support: This work was supported by the European Research Council under the European Union’s Horizon 2020 research and innovation program (grant 694913), the Else Kröner-Fresenius Stiftung in support of the German Conns Registry-Else-Kröner Hyperaldosteronism Registry (2013_A182 and 2015_A171), and the Deutsche Forschungsgemeinschaft (RE 752/20-1). Disclosure Summary: The author has nothing to disclose.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2765264971
FWCI: 4.025
Cites: 18
Cited by: 43
Related to: 10